Royed TrainingMaster patient-based, pricing & scenario-driven pharma forecasting with hands-on models. Think strategically. Forecast confidently.
#PharmaForecasting #PharmaStrategy #PharmaBD #MarketAccess #RoyedTraining
Industry ExaminerWho wins the obesity-drug race may hinge on deal architecture, not just data. We unpack Pfizer’s challenge to Novo Nordisk’s Metsera bid—focusing on a 30-month outside date, restrictive covenants and an unusual cash structure—and what it means for investors and founders navigating GLP-1.
Read the full analysis: https://biotech.industryexaminer.com/the-obesity-wars-go-to-court-pfizer-says-novos-metsera-bid-is-a-moat-not-a-merger/
#GLP1 #Biotech #MergersAndAcquisitions #Antitrust #PharmaStrategy #TechNews
Unlock expertise in #marketaccess #strategicmanagement #marketapprovals, and hashtag#compliance across global markets. The #ExecutiveProgram is designed for middle and top management professionals. Take demo today. #royedtraining
🚀 The Ultimate Pharma Business & Market Strategy Program! 🌍
#PharmaLeadership MarketAccess #HEOR #RegulatoryAffairs #PharmaStrategy #BusinessDevelopment #Forecasting #PharmaMarketing #RoyedTraining
Dominic TyerAfter the pandemic's digital pivot, pharma's future commercial model remains uncertain
#pharma #PharmaStrategy #digitaltransformation #digitalstrategy
Pharma companies still slow to adopt hybrid sales rep and digital commercial models – survey
After the pandemic spurred a rush to digital commercialization strategies, pharma companies realized they needed to evolve their traditional sales rep-led models. However, they’re still unsure about how best to do that, according to a new survey of pharma leaders. One key uncertainty is around exactly what a hybrid commercial
Change of guard at drug price watchdog: ICER founder Steve Pearson to step down after 17 years
#pharma #PharmaceuticalIndustry #PharmaCompanies #PharmaceuticalCompanies #pharmastrategy #PharmaPricing #ICER #HEOR #MarketAccess
Change of guard at drug price watchdog: ICER founder Steve Pearson to step down after 17 years
After growing the Institute for Clinical and Economic Review (ICER) into an influential drug pricing watchdog, Steve Pearson, M.D., is stepping down. | After growing the Institute for Clinical and Economic Review into an influential drug pricing watchdog, Steve Pearson is stepping down.
It’s a newly created role in our expanding Thought-Leadership practice and will cover commercial, clinical and medical affairs’ operations in pharma
https://www.linkedin.com/jobs/view/3360890668/?refId=hmy6BC8GTyiWUXU4o6iUiw%3D%3D
#pharma #digitaltransformation #pharmastrategy #strategy #consulting #medicalaffairs #clinicaltrials #customerexperience #CX #hiring
Pernille WeissThis is serious and we must turn the curve📈❗️
The coming legislative work on EU #pharmastrategy and #healthresearch MUST put the puzzle and needed ressources together‼️
#eupol #research
RT @alliancerm: What does the pipeline for #CGT clinical trials look like? North America is ahead in total trials across all phases, while Asia Pacific takes the lead in new phase I trials. Europe however remains stagnant.
Read our H1 2022 rep…
🐦🔗: https://nitter.eu/WeissPernille/status/1572258482253926403
EU must develop the best #pharmastrategy of all to secure #Health4All and make Europe the global hotspot #lifescience
Today @EFPIA and great colleauges from @EPPGroup started a cocreative process to deliver!
🙏🏻@CristianSBusoi @mgracacarvalho @MEP_Ehler @TomislavSokol et al
RT @LarsFruergaard: A big thank you to @weisspernille for hosting a great life science round table @EFPIA with leading MEPs from @EPPGroup and for being a …
🐦🔗: https://nitter.eu/WeissPernille/status/1541852192222711809
Pernille Weiss (@WeissPernille)
EU must develop the best #pharmastrategy of all to secure #Health4All and make Europe the global hotspot #lifescience Today @EFPIA and great colleauges from @EPPGroup started a cocreative process to deliver! 🙏🏻@CristianSBusoi @mgracacarvalho @MEP_Ehler @TomislavSokol et al